skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

About Malcolm

Washington DC, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}

+13 year(s) experience

Malcom Spicer
Malcolm has expertly covered the OTC drug and nutritional supplement industries and markets for more than a decade and currently is Senior Editor at Informa Pharma Intelligence’s HBW Insights. He provides authoritative and highly analytical insight into how and why the US Food and Drug Administration regulates OTC drug, including homeopathics, and nutritional supplement manufacturing and marketing and also how companies competing in these industries can most efficiently and effectively comply with FDA regulations, the cornerstone for their success.
Previously, Malcolm covered these industries for the Tan Sheet (now part of HBW Insight), joining the Tan Sheet as Managing Editor in August 2006. He has continued to lead coverage of consumer health products as the consumer sector content has evolved at Informa and he collaborates on coverage strategy with editors at Pink Sheet and other publications. Malcolm also has had experience in covering US health care policy and the global telecommunications industry as well as reporting on topics from litigation to lifestyles, and from crime to commerce for daily newspapers.


Analyst Articles

Articles by Malcolm

  • HBW Insight

    With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives

    By Malcolm Spicer 07 Mar 2019

    Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.

    Topic FDA